ReviewCurrent pharmaceutical design2016
Large Porous Hollow Particles: Lightweight Champions of Pulmonary Drug Delivery.
Review in Current pharmaceutical design, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 57 citations in OpenAlex.
- mRNA Lipid Nanoparticles for Cell Engineering in Vivo and in Vitro: Current Applications and Future Directions.MedComm · 2026Review
- Alternative Techniques for Porous Microparticle Production: Electrospraying, Microfluidics, and Supercritical COPharmaceutical research · 2025Review
- Engineering Large Porous Mannitol-PVA Microparticles for Extended Drug Delivery via Spray Drying.Pharmaceutics · 2025Article
- Solubilising and Aerosolising Cannabidiol Using Methyl β-Cyclodextrin and Human Serum Albumin.AAPS PharmSciTech · 2025Article
- Optimization, In Vitro, and In Silico Characterization of Theophylline Inhalable Powder Using Raffinose-Amino Acid Combination as Fine Co-Spray-Dried Carriers.Pharmaceutics · 2025Article
- Liposome-Based Nanoparticle Delivery Systems for Lung Diseases: Opportunities and Challenges.International journal of nanomedicine · 2025Review
- Nanotherapy to Reshape the Tumor Microenvironment: A New Strategy for Prostate Cancer Treatment.ACS omega · 2024Review
- State-of-the-Art Review on Inhalable Lipid and Polymer Nanocarriers: Design and Development Perspectives.Pharmaceutics · 2024Review
- Excipients for Novel Inhaled Dosage Forms: An Overview.AAPS PharmSciTech · 2024Review
- Investigation of paeonol in dermatological diseases: an animal study review.Frontiers in pharmacology · 2024Review
- Inhalation Dosage Forms: A Focus on Dry Powder Inhalers and Their Advancements.Pharmaceuticals (Basel, Switzerland) · 2023Review
- Development of Large Hollow Particles for Pulmonary Delivery of Cyclosporine A.Pharmaceutics · 2023Article
- Dry Powder Formulation of Simvastatin Nanoparticles for Potential Application in Pulmonary Arterial Hypertension.Pharmaceutics · 2022Article
- The future of dry powder inhaled therapy: Promising or discouraging for systemic disorders?International journal of pharmaceutics · 2022Review
- The emergence of nanoporous materials in lung cancer therapy.Science and technology of advanced materials · 2022Review
- PLGA-based biodegradable microspheres in drug delivery: recent advances in research and application.Drug delivery · 2021Review
- Microencapsulated Isoniazid-Loaded Metal-Organic Frameworks for Pulmonary Administration of Antituberculosis Drugs.Molecules (Basel, Switzerland) · 2021Article
- Pulmonary siRNA delivery for lung disease: Review of recent progress and challenges.Journal of controlled release : official journal of the Controlled Release Society · 2021Review
- A Pathway From Porous Particle Technology Toward Tailoring Aerogels for Pulmonary Drug Administration.Frontiers in bioengineering and biotechnology · 2021Review
- COVID-19: Pathophysiology, treatment options, nanotechnology approaches, and research agenda to combating the SARS-CoV2 pandemic.Life sciences · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
The deep lungs provide an efficient pathway for drugs to transport into the systemic circulation, as the extremely large surface area and thin epithelial membrane enable rapid drug transport to the blood stream. To penetrate into the deep lungs, aerosol particles with aerodynamic diameters of 1-3 µm are optimal. Large porous hollow particles (LPHPs) can achieve this aerodynamic size range through enhanced porosity within the particles (typically < 0.4 g/cm(3)), which aerodynamically balances the large particle size (> 5 µm, up to 30 µm). The physical properties of these particles provide some key advantages compared to their small, nonporous counterparts through enhanced dispersibility, efficient deep lung deposition, and avoidance of phagocytic clearance. This review highlights the potential of LPHPs in pulmonary delivery of systemic drugs, with a focus on their critical attributes and key formulation aspects. In addition, three examples of LPHPs under development are presented to emphasize the potential of this technology to treat systemic diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.